-
Article
Open AccessTracking the origins and drivers of subclonal metastatic expansion in prostate cancer
Tumour heterogeneity in primary prostate cancer is a well-established phenomenon. However, how the subclonal diversity of tumours changes during metastasis and progression to lethality is poorly understood. He...
-
Article
Open AccessSNES makes sense? Single-cell exome sequencing evolves
Technologies for single-cell sequencing are improving steadily. A recent study describes a new method for interrogating all coding sequences of the human genome at single-cell resolution.
-
Article
Correction: Corrigendum: Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue
Nat. Genet. 47, 367–372 (2015); published online 2 March 2015; corrected after print 5 May 2015 In the version of this article initially published, author Manasa Ramakrishna was omitted from the author list. T...
-
Article
Subclonal diversification of primary breast cancer revealed by multiregion sequencing
Whole-genome and targeted sequencing of multiple sections of each of 50 tumors reveals varying degrees of subclonal diversification and genomic heterogeneity.
-
Article
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
We analysed whole-genome sequences of 560 breast cancers to advance understanding of the driver mutations conferring clonal advantage and the mutational processes generating somatic mutations. We found that 93...
-
Article
Open AccessMutational signatures of ionizing radiation in second malignancies
Ionizing radiation is a potent carcinogen, inducing cancer through DNA damage. The signatures of mutations arising in human tissues following in vivo exposure to ionizing radiation have not been documented. Here,...
-
Article
Open AccessTracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing
Single-cell micro-metastases of solid tumors often occur in the bone marrow. These disseminated tumor cells (DTCs) may resist therapy and lay dormant or progress to cause overt bone and visceral metastases. Th...
-
Article
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
The early detection of relapse following primary surgery for non-small-cell lung cancer and the characterization of emerging subclones, which seed metastatic sites, might offer new therapeutic approaches for l...
-
Article
Open AccessRecurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma
Osteosarcoma is a primary malignancy of bone that affects children and adults. Here, we present the largest sequencing study of osteosarcoma to date, comprising 112 childhood and adult tumours encompassing all...
-
Article
Open AccessPan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors
Homozygous deletions are rare in cancers and often target tumour suppressor genes. Here, we build a compendium of 2218 primary tumours across 12 human cancer types and systematically screen for homozygous dele...
-
Article
Correction: Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Nature 545, 446–451 (2017); doi:10.1038/nature22364 For 6 of the 96 patients included in this Article (patients CRUK0014, CRUK0030, CRUK0048, CRUK0059, CRUK0096 and CRUK0097) incorrect tumour volumetric data a...
-
Article
Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets
Prostate cancer represents a substantial clinical challenge because it is difficult to predict outcome and advanced disease is often fatal. We sequenced the whole genomes of 112 primary and metastatic prostate...
-
Article
Open AccessRecurrent rearrangements of FOS and FOSB define osteoblastoma
The transcription factor FOS has long been implicated in the pathogenesis of bone tumours, following the discovery that the viral homologue, v-fos, caused osteosarcoma in laboratory mice. However, mutations of FO...
-
Article
Open AccessTiming somatic events in the evolution of cancer
Cancer arises through the accumulation of somatic mutations over time. An understanding of the sequence of events during this process should allow both earlier diagnosis and better prediction of cancer progres...
-
Article
Open AccessCharacterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features
Racial/ethnic disparities in breast cancer mortality continue to widen but genomic studies rarely interrogate breast cancer in diverse populations. Through genome, exome, and RNA sequencing, we examined the mo...
-
Article
Open AccessTime series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations
Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) and inhibits its ...
-
Article
Neutral tumor evolution?
-
Article
Open AccessAuthor Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors
The original version of this Article contained an error in the author affiliations. The affiliation of Kevin P. White with Tempus Labs, Inc., Chicago, IL, USA was inadvertently omitted.This has now been correc...
-
Article
Open AccessAuthor Correction: Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features
The original version of this Article contained an error in the author affiliations. The affiliation of Kevin P. White with Tempus Labs, Inc. Chicago, IL, USA was inadvertently omitted. This has now been correc...
-
Article
Open AccessAuthor Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors
The original version of this Article omitted a declaration from the competing interests statement, which should have included the following: ‘K.P.W. is President of Tempus Lab, Inc., Chicago, IL, USA’. This ha...
